# Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

> **NCT00428714** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 73 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** enzastaurin

## Key facts

- **NCT ID:** NCT00428714
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-06
- **Final completion:** 2011-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428714, "Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00428714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*